Regeneron Pharmaceuticals (REGN) Interest Coverage Ratio (2009 - 2026)
Regeneron Pharmaceuticals' quarterly Interest Coverage Ratio came in at 49.84 in Q1 2026, down 26.72% year-on-year from 68.01 in Q1 2025, and down 30.9% quarter-over-quarter from 72.12 in Q4 2025.
Regeneron Pharmaceuticals has reported Interest Coverage Ratio for 17 years, with the latest figure at 49.84 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 26.72% year-over-year to 49.84; the trailing twelve-month figure through Mar 2026 stood at 75.61 (down 5.66% YoY), and the FY2025 full-year result was 81.69, up 12.99% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 49.84, down from 72.12 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 299.86 in Q2 2025, with the low at 46.67 in Q1 2024.
- Average Interest Coverage Ratio over 5 years is 81.58, with a median of 68.01 recorded in 2025.
- Year-over-year, Interest Coverage Ratio tumbled 64.8% in 2022 and soared 314.92% in 2025.
- Tracing REGN's Interest Coverage Ratio over 5 years: stood at 65.91 in 2022, then dropped by 19.34% to 53.16 in 2023, then soared by 77.38% to 94.3 in 2024, then retreated by 23.52% to 72.12 in 2025, then plunged by 30.9% to 49.84 in 2026.
- The last three Interest Coverage Ratio figures came in at 49.84 (Q1 2026), 72.12 (Q4 2025), and 53.2 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -36.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.84 |
| Dec 31, 2025 | 72.12 |
| Sep 30, 2025 | 53.20 |
| Jun 30, 2025 | 299.86 |
| Mar 31, 2025 | 68.01 |
| Dec 31, 2024 | 94.30 |
| Sep 30, 2024 | 85.47 |
| Jun 30, 2024 | 72.27 |
| Mar 31, 2024 | 46.67 |
| Dec 31, 2023 | 53.16 |
| Sep 30, 2023 | 62.42 |
| Jun 30, 2023 | 53.78 |
| Mar 31, 2023 | 52.59 |
| Dec 31, 2022 | 65.91 |
| Sep 30, 2022 | 79.98 |
| Jun 30, 2022 | 84.73 |
| Mar 31, 2022 | 92.54 |
| Dec 31, 2021 | 187.21 |
| Sep 30, 2021 | 130.08 |
| Jun 30, 2021 | 232.44 |
| Mar 31, 2021 | 76.21 |
| Dec 31, 2020 | 78.85 |
| Sep 30, 2020 | 40.04 |
| Jun 30, 2020 | 67.67 |
| Mar 31, 2020 | 114.77 |
| Dec 31, 2019 | 100.85 |
| Sep 30, 2019 | 94.68 |
| Jun 30, 2019 | 39.45 |
| Mar 31, 2019 | 62.34 |
| Dec 31, 2018 | 97.04 |
| Sep 30, 2018 | 84.72 |
| Jun 30, 2018 | 90.17 |
| Mar 31, 2018 | 88.63 |
| Dec 31, 2017 | 89.56 |
| Sep 30, 2017 | 90.57 |
| Jun 30, 2017 | 101.89 |
| Mar 31, 2017 | 57.40 |
| Dec 31, 2015 | 64.03 |
| Sep 30, 2015 | 228.82 |
| Jun 30, 2015 | 125.49 |
| Mar 31, 2015 | 45.96 |
| Dec 31, 2014 | 38.96 |
| Sep 30, 2014 | 20.41 |
| Jun 30, 2014 | 22.41 |
| Mar 31, 2014 | 16.50 |
| Dec 31, 2013 | 16.73 |
| Sep 30, 2013 | 20.18 |
| Jun 30, 2013 | 13.91 |
| Mar 31, 2013 | 13.11 |
| Dec 31, 2012 | 12.67 |
| Sep 30, 2012 | 17.73 |
| Jun 30, 2012 | 7.79 |
| Mar 31, 2012 | 1.99 |
| Dec 31, 2011 | -4.80 |
| Sep 30, 2011 | -14.39 |
| Jun 30, 2011 | -14.90 |
| Mar 31, 2011 | -11.02 |
| Dec 31, 2010 | -5.20 |
| Sep 30, 2010 | -14.37 |
| Jun 30, 2010 | -10.13 |
| Mar 31, 2010 | -13.86 |
| Dec 31, 2009 | -22.44 |
| Sep 30, 2009 | -2.22 |